Rubicon Research Secures ₹140 Crore Pre-IPO Funding from TIMF Holdings and 360 ONE

Mumbai, 22 September 2025: Rubicon Research has raised ₹140 crore in a pre-IPO funding round, attracting investment from TIMF Holdings, owned by US-based Think Investments, and 360 ONE funds. The capital infusion comes ahead of the company’s much-anticipated public listing, expected later this year.

Founded by the Pilgaonkar and Sancheti families, Rubicon Research focuses on pharmaceutical formulations and research-driven innovation. With its headquarters in Mumbai and growing global footprint, the company is strengthening its specialty product portfolio to target regulated markets, particularly the United States.

General Atlantic’s Stake Declines to 52.15% After ₹484.47 per Share Deal

As part of the transaction, General Atlantic Singapore RR Pte. Ltd, one of the company’s promoters, transferred 28.89 lakh equity shares at ₹484.47 per share to TIMF Holdings and 360 ONE funds.

General Atlantic earlier held 8.37 crore shares (54.01%). Following the transfer, it retains a 52.15% majority stake with 8.08 crore shares. This marks General Atlantic’s second divestment in recent months, following the August 2025 transfer of 51.60 lakh shares to Amansa Investments at the same price point.

The recurring offloads suggest a strategic stake reshuffling as Rubicon positions itself for its upcoming listing.

IPO Roadmap Adjusted Amid Fresh Fund Deployment Plans

The Mumbai-based pharmaceutical company is preparing to file for its maiden IPO. Initially, the issue was planned with a ₹500 crore fresh issue and a ₹585 crore offer-for-sale (OFS). The final structure will be disclosed in the Red Herring Prospectus (RHP) closer to launch.

Proceeds from the fresh issue are earmarked for debt repayment, acquisitions, strategic initiatives, and general corporate purposes, underlining Rubicon’s focus on balance sheet strength and expansion opportunities.

Acquisitions of ₹149 Crore Strengthen Manufacturing Footprint

In June 2025, Rubicon Research acquired Alkem Laboratories’ formulations facility in Pithampur, Madhya Pradesh, in an all-cash deal worth ₹149 crore. The move expanded its production capacity alongside its two existing US FDA-inspected facilities in India.

By integrating this asset, Rubicon is positioned to enhance scale and regulatory readiness as it deepens its presence in export markets.

Strong R&D Pipeline with 69 USFDA-Approved Products

Rubicon Research has built a significant innovation pipeline:

• 69 products approved by the US Food and Drug Administration (USFDA).
• 19 applications currently under review.
• 46 products in different development stages.

The company also operates two R&D centres, one in India and another in Canada, both inspected by the USFDA. Facilities in India are additionally accredited by the Maharashtra FDA (WHO-GMP) and Health Canada, highlighting robust regulatory compliance.

Rubicon Research’s ₹140 crore pre-IPO funding highlights its momentum ahead of listing, supported by strategic stake realignments, regulatory compliance, and manufacturing expansion. The company’s focus on debt reduction, acquisitions, and R&D strength indicates clear growth priorities as it prepares for its IPO.

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations